BVP portfolio companies Vivalyx, Noah Labs and Hy2Care have each received prominent public recognition in recent weeks, in Germany and the United States.
Noah Labs, the Berlin-based company developing voice biomarkers for heart failure monitoring, concluded its MedTech Innovator 2026 journey with a feature on the Nasdaq billboard in Times Square, New York. The company received FDA Breakthrough Device Designation earlier this year and now moves into its next phase of growth.
Hy2Care, the Geleen-based University of Twente spin-off developing the CartRevive injectable hydrogel implant for traumatic knee cartilage defects, was part of the same MedTech Innovator cohort and was also featured on the Nasdaq billboard. The 2026 cohort comprised 65 companies selected from 1,835 applicants. Hy2Care is preparing a U.S. clinical trial following a EUR 4.5 million financing in 2025.
Besides great news from the MedTech Innovator cohort, Vivalyx, which develops technology for organ transplantation, was featured in Handelsblatt among the top start-ups from North Rhine-Westphalia. The selection was supported by Scale-up.NRW, the NRW Ministry of Economic Affairs, Industry, Climate Action and Energy, digihub Düsseldorf/Rheinland, Gateway Factory and the Start2 Group. Vivalyx appeared alongside Skleo Health, experial and syte.
For BVP, the coverage reflects a consistent pattern: companies built on scientific breakthroughs, backed from Benelux and Germany, reaching international audiences.